Clinical trials
Open Label clinical trials
Below are recruiting open label clinical trials, each written for real people, not researchers. We’re tracking 366 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07091175RecruitingPhase 2
Dupilumab for nephrotic syndrome in children
This trial tests if dupilumab can help children with nephrotic syndrome who still have relapses despite standard treatments. It aims to find a better way to control the disease and reduce steroid side effects.
Singapore, SingaporeAges 6–18 - NCT06968364Recruiting
Testing a device to predict preterm birth risk
This trial tests a new medical device to see if it can help predict preterm birth in pregnant women who are having early contractions. It may help doctors decide which patients need treatment to prevent early delivery.
A CoruñaAges 18 years+ - NCT07373210Recruiting
Placebo pills for hip surgery pain in teens and young adults
This study tests whether taking placebo pills (pills with no active drug) can help manage pain after a specific hip surgery, called Bernese Periacetabular Osteotomy (PAO), in people with a hip condition called developmental dysplasia. The goal is to see if using placebos can reduce the need for pain medications and help with recovery.
San Francisco, CaliforniaAges 13–40 - NCT06365892Recruiting
Open-label placebo for pain after scoliosis surgery
This trial tests whether taking a placebo pill that you know is a placebo (open-label placebo) can help reduce pain after spinal fusion surgery for scoliosis. It compares the placebo to standard care in adolescents aged 11-17.
San Francisco, CaliforniaAges 10–18 - NCT07633756RecruitingPhase 1
Testing RB1-negative Leiomyosarcoma Treatment with REC-617
This study tests a new drug called REC-617 in patients with a rare muscle cancer (leiomyosarcoma) that has spread or cannot be surgically removed. The drug targets cancer cells that lack a specific protein called RB1, and you must have already tried at least one other cancer treatment before joining.
Houston, TexasAges 18 years+ - NCT07663838RecruitingPhase 1
Vaginal treatment for bacterial vaginosis
This study tests a new vaginal treatment for bacterial vaginosis (BV), a common infection causing itching, odor, and discharge. It aims to see if the treatment is safe and works well.
Beijing, Beijing MunicipalityAges 18–50 - NCT07456891RecruitingPhase 3
Continued access to remibrutinib after a prior study
This trial lets people who have been benefiting from remibrutinib in an earlier Novartis study continue receiving the drug after their original study ends. It's an open-label roll-over study, meaning everyone knows they're getting remibrutinib and it's designed to provide ongoing treatment for those who need it.
SofiaAges 12–100 - NCT07162571Enrolling by invitationPhase 1/Phase 2
Engineered immune cells for advanced leukemia or lymphoma
This study tests a new type of immune therapy called CAR-T cells, which are made from your own blood cells to find and attack cancer. It is for adults with leukemia or lymphoma that has come back or is hard to treat.
MinskAges 18 years+ - NCT05980949RecruitingPhase 3
Long-term safety study of KarXT for Alzheimer's psychosis
This trial tests the long-term safety of an investigational drug called KarXT for people with psychosis caused by Alzheimer's disease. It is for those who have already completed a previous KarXT study and want to continue treatment.
Homewood, AlabamaAges 55–90 - NCT07857733RecruitingPhase 3
Extended treatment study for complex regional pain syndrome
This study gives an extended course of neridronate infusions to people who completed the earlier AMBTX-01-301 trial, to see if longer treatment safely keeps easing their chronic pain and other symptoms of complex regional pain syndrome (a long-lasting pain condition, often after an injury).
Phoenix, ArizonaAges 18 years+ - NCT06664814RecruitingPhase 2
Study of ManNAc for kidney diseases with proteinuria
This study tests a new drug called ManNAc for people with certain kidney diseases (FSGS, MCD, or MN) that cause protein in the urine. The goal is to see if this drug can help reduce protein loss and improve kidney health.
Bethesda, MarylandAges 18–115 - NCT07226986RecruitingPhase 1/Phase 2
Study of AMO959 with Lutetium-177 and ARPI for prostate cancer
This trial tests a new combination therapy for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. It combines an experimental drug (AMO959) with a targeted radiation treatment (Lutetium-177) and a standard hormone therapy to see if it helps control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT07459647RecruitingPhase 2
Long-term study of ML-007C-MA for schizophrenia
This trial tests a new drug, ML-007C-MA, for adults with schizophrenia who may benefit from ongoing treatment. It aims to see how safe and effective the drug is over a longer period.
Little Rock, ArkansasAges 18–65 - NCT07723703RecruitingPhase 1
Study of a new drug for acute myeloid leukemia and related blood cancer
This trial is testing a new medicine called AMX-883 for people with a type of blood cancer called acute myeloid leukemia (AML) or a high-risk blood disorder called myelodysplastic syndrome (MDS) that has come back or not responded to other treatments. The study hopes to see if the drug is safe and works, either alone or combined with another drug.
Fairfax, VirginiaAges 18 years+ - NCT06154252RecruitingPhase 2/Phase 3
Study of CABA-201 for active myositis in adults and children
This trial tests a new treatment called CABA-201, which uses your own immune cells modified to attack the overactive cells causing myositis. It is for people with active disease that hasn't improved enough with standard therapies.
Orange, CaliforniaAges 6–75 - NCT03392337Recruiting
Narrowband UVB light therapy for moderate to severe plaque psoriasis
This study tests whether narrowband ultraviolet B (UVB) light given three times a week for 12 weeks improves moderate-to-severe plaque psoriasis. It is an “open-label” pilot, meaning everyone gets the UVB treatment and researchers track how your skin responds.
East Windsor, New JerseyAges 18 years+ - NCT04888975Recruiting
Device study for one-arm swelling after lymph surgery
This study tests a medical device (Dayspring Technology) to reduce swelling in the arm caused by breast cancer treatment and lymph surgery. You may be eligible if you have one-sided arm swelling after lymphatic surgery and meet safety checks for the device.
Palo Alto, CaliforniaAges 18 years+ - NCT05607329Recruiting
Surgery plus chemo versus chemo alone for ovarian cancer relapse
This trial tests whether doing additional surgery to remove visible tumor (“secondary cytoreduction”) before chemotherapy helps compared with chemotherapy alone. It’s for ovarian (or related) cancer that came back after prior PARP inhibitor maintenance and platinum chemotherapy.
Hangzhou, ZhejiangAges 18–70 - NCT05366452Recruiting
Early heart pump implant for shock after a heart attack
This trial studies whether putting in a small heart pump early (through the leg) helps people with a heart attack complicated by severe heart weakness (“cardiogenic shock”) compared with standard treatment. It aims to improve survival and recovery by supporting blood flow sooner.
Marseille, Bouche DU RhoneAges 18–80 - NCT06079788RecruitingPhase 3
ACTH for children with frequently relapsing nephrotic syndrome
This trial tests if a hormone called ACTH can help children with nephrotic syndrome who have frequent relapses or need steroids to stay in remission. It aims to find a treatment that may reduce the need for steroids and prevent relapses.
Wuhan, HubeiAges 2–14 - NCT06082180RecruitingPhase 3
Preventive neck lymph node removal in low-risk thyroid cancer
This trial is for people with low-risk papillary thyroid cancer. It compares two surgical approaches: one that removes just the thyroid gland, and another that also removes some lymph nodes in the center of the neck as a preventive measure. The goal is to see if removing these lymph nodes helps prevent the cancer from coming back.
Beijing, Beijing MunicipalityAges 18–70 - NCT07855250RecruitingPhase 1
How rilzabrutinib interacts with common drug transporters
This study checks how the investigational medicine rilzabrutinib affects proteins in your body that help clear certain drugs. It helps make sure other medications you take are safe and work properly.
Québec, QuebecAges 18–55 - NCT07864207RecruitingPhase 1/Phase 2
Study of IDP-121 for small cell lung cancer that stopped responding to platinum
This trial tests a new drug, IDP-121, alone or with another chemo drug, for people with small cell lung cancer that came back after initial treatment. The goal is to see if it can shrink tumors and help people live longer.
BarcelonaAges 18 years+ - NCT04557462RecruitingPhase 3
Long-term safety study of iptacopan for IgA nephropathy
This study provides continuing treatment with iptacopan for people with IgA nephropathy who have completed a previous iptacopan trial. It aims to see how safe and tolerable the drug is over a longer period.
Glendale, ArizonaAges 18–100
Hear when a new Open Label trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for open label?
- Yes. Clin2 currently lists 366 recruiting open label studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a open label trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a open label trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.